Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Urology Devices Play to Large and Growing Procedure Volumes

This article was originally published in Start Up

Executive Summary

Last year saw a surprising number of investments in devices for urology but the development activity in this space should not be surprising, given that prostate disease-both prostate cancer and BPH-are diseases of aging, setting in after age 40 when hormonal changes may cause the prostate to enlarge. BPH, for example, affects more than 50% of men age 60 and older and 90% of men age 70 and older. Prostate cancer is the second-leading cause of carcinoma death in men. These demographic trends are reflected in the rapid growth in surgical procedures for the treatment of prostate disease, many of which are projected to grow at high double-digit rates in major global economies, according to a series of reports detailing surgical volumes and trends by country, published by the Medtech Insight division of Elsevier Business Intelligence.

You may also be interested in...



The Generics Bulletin Top 50, Part One: Industry Top 10 Reshaped By Leaders’ Transformations

A new entrant into the top five global generics and biosimilars companies shows how transformations for some of the leading off-patent players are reshaping the industry landscape, with more major changes in the pipeline. We examine the 10 leaders of the pack in the first instalment of this year’s Generics Bulletin Top 50.

Syngene COO On Delivering Cost Gains For mRNA Products

Syngene’s COO, Mahesh Bhalgat, tells Scrip the firm is better placed than some peers to serve clients for biologics-based advanced therapies and address the cost element for new modalities like mRNA. He also outlines the research, development and manufacturing services company' capabilities in oligonucleotide-based therapeutics, an area that's seeing growing interest.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: what Amgen’s $3.7bn ChemoCentryx buy means; Lilly’s CEO on US drug pricing legislation; Pfizer’s GBT acquisition; new data for Amgen’s KRAS inhibitor combo; and a major China ADC alliance for Sanofi.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

MT037660

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel